POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022.
June 22, 2022
· 2 min read